Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Neuroendocrine Tumors 60Breast Neoplasms 22Thyroid Neoplasms 20Neoplasms 20Multiple Endocrine Neoplasia Type 1 20Carcinoma, Renal Cell 20Melanoma 19Carcinoma, Non-Small-Cell Lung 19Adrenocortical Carcinoma 19Small Cell Lung Carcinoma 17Thyroid Cancer, Papillary 16Colorectal Neoplasms 16Thyroid Carcinoma, Anaplastic 15Carcinoma, Neuroendocrine 15Carcinoma, Medullary 14Prostatic Neoplasms 13Pheochromocytoma 13Pancreatic Neoplasms 13Lung Neoplasms 13Carcinoma, Hepatocellular 13Carcinoid Tumor 13Insulinoma 12Uterine Cervical Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 11Head and Neck Neoplasms 11Adenocarcinoma, Follicular 11Salivary Gland Neoplasms 10Pituitary Neoplasms 10Colonic Neoplasms 10

Interventions

GSK3352589 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Irritable Bowel Syndrome × Endocrine × Clear all
NCT03154086 2019-08-09

A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers

GlaxoSmithKline

Phase 1 Completed
68 enrolled 80 charts
Endocrine

Multiple Endocrine Neoplasia Type 2a, Irritable Bowel Syndrome

NCT02727283 2017-05-08

A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers

GlaxoSmithKline

Phase 1 Completed
16 enrolled
Endocrine

Multiple Endocrine Neoplasia Type 2a, Irritable Bowel Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡